Embecta Corp. Declares Quarterly Cash Dividend of $0.15 per Share

Embecta Corp. declares a $0.15 quarterly dividend, payable June 13, 2025, to shareholders of record on May 28, 2025.

Quiver AI Summary

Embecta Corp. announced a quarterly cash dividend of $0.15 per share for its common stock, which will be paid on June 13, 2025, to stockholders recorded by May 28, 2025. Embecta, a global diabetes care company with a century-long history in insulin delivery, aims to enhance the lives of people with diabetes through innovative solutions and collaboration among its workforce of approximately 2,000 employees worldwide. For more details, visit embecta.com or their social media platforms.

Potential Positives

The declaration of a quarterly cash dividend demonstrates the company's financial stability and commitment to returning value to shareholders.
The dividend payment could enhance investor confidence and attract potential investors looking for income-generating stocks.
The upcoming dividend reflects the company’s ongoing profitability and operational success, suggesting a positive outlook for future performance.

Potential Negatives

The dividend amount of $0.15 may indicate limited financial growth potential for the company, which could concern investors looking for more substantial returns.
Declaring a cash dividend could divert funds away from potential growth investments or innovative projects, which may impact long-term growth.
By scheduling the dividend payment for June 13, 2025, the company may signal that it is focusing on short-term gains rather than long-term strategic initiatives, raising concerns among stakeholders about overall company direction.

FAQ

What is the amount of the declared dividend by Embecta Corp?

Embecta Corp has declared a quarterly cash dividend of $0.15 per share of common stock.

When will the dividend be paid to stockholders?

The dividend will be payable on June 13, 2025, to stockholders of record as of May 28, 2025.

What is the significance of Embecta Corp's dividend announcement?

The dividend announcement reflects Embecta's financial commitment to its shareholders and its strong performance in the diabetes care sector.

How can I learn more about Embecta Corp?

For more information, visit Embecta's official website at embecta.com or follow them on social media platforms.

What is Embecta Corp's mission in diabetes care?

Embecta aims to empower people with diabetes through innovative solutions and a century-long legacy in insulin delivery.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$EMBC Insider Trading Activity

$EMBC insiders have traded $EMBC stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $EMBC stock by insiders over the last 6 months:

DAVID F MELCHER purchased 13,000 shares for an estimated $177,646
MILTON MAYO MORRIS sold 3,100 shares for an estimated $50,782

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$EMBC Hedge Fund Activity

We have seen 92 institutional investors add shares of $EMBC stock to their portfolio, and 176 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC removed 1,277,252 shares (-53.1%) from their portfolio in Q4 2024, for an estimated $26,375,253
UBS GROUP AG added 749,363 shares (+1400.6%) to their portfolio in Q4 2024, for an estimated $15,474,345
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 739,461 shares (+inf%) to their portfolio in Q4 2024, for an estimated $15,269,869
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 540,192 shares (+19.8%) to their portfolio in Q4 2024, for an estimated $11,154,964
SIO CAPITAL MANAGEMENT, LLC added 425,574 shares (+inf%) to their portfolio in Q4 2024, for an estimated $8,788,103
MARSHALL WACE, LLP removed 284,246 shares (-77.2%) from their portfolio in Q4 2024, for an estimated $5,869,679
CRAWFORD INVESTMENT COUNSEL INC removed 279,558 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $5,772,872

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$EMBC Analyst Ratings

Wall Street analysts have issued reports on $EMBC in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Morgan Stanley issued a "Overweight" rating on 12/02/2024
BTIG issued a "Buy" rating on 11/27/2024

To track analyst ratings and price targets for $EMBC, check out Quiver Quantitative's $EMBC forecast page.

$EMBC Price Targets

Multiple analysts have issued price targets for $EMBC recently. We have seen 2 analysts offer price targets for $EMBC in the last 6 months, with a median target of $23.0.

Here are some recent targets:

Kallum Titchmarsh from Morgan Stanley set a target price of $20.0 on 12/02/2024
Marie Thibault from BTIG set a target price of $26.0 on 11/27/2024

Full Release

PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.

About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn , Facebook , and Instagram .

Contacts:

Media
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922
Contact Media Relations

Investors
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR